Shr-8068

Advanced Renal Cell Carcinoma

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 1/2Active

CC

45/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 81/ 100

Competitive context

18 Active assets in the Advanced Renal Cell Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Trebananib National Cancer Institute (NCI)	Phase 2	BB
CLOSTRIDIUM BUTYRICUM MIYAIRI 588 City of Hope Medical Center	Phase 3	BB
Bms-907351 National Cancer Institute (NCI)	Phase 2	B
Telaglenastat Calithera Biosciences, Inc	Phase 2	B
Dfn-15 Case Comprehensive Cancer Center	Phase 2	B

View all 32 →

Same molecule, other indications

Shr-8068 is also rated in:

Advanced Non-small Cell Lung CancerDormant

BB

Indicative ·

70 / 100

hepatocellular carcinomaDormant

B

Indicative ·

62 / 100

Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence RiskDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.